ORIGINAL ARTICLE

Therapeutic effects of human mesenchymal stem cell microvesicles in an ex vivo perfused human lung injured with severe *E. coli* pneumonia

Jeonghyun Park,¹ Seonguk Kim,² Hyungsun Lim,³ Airan Liu,¹ Shuling Hu,¹ JaeHoon Lee,¹ Hanjing Zhuo,¹ Qi Hao,¹ Michael A Matthay,¹ Jae-W Lee¹

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/thoraxjnl-2018-211576>).

¹Departments of Anesthesiology, Medicine, and Cardiovascular Research Institute, University of California, San Francisco, California, USA

²Department of Pediatrics, Korea University Guro Hospital, Seoul, The Republic of Korea

³Department of Anesthesiology, Jeonbuk National University Medical School, Jeonju, The Republic of Korea

Correspondence to

Dr Jae-W Lee, Department of Anesthesiology, University of California San Francisco, San Francisco CA 94143, USA; leejw@anesthesia.ucsf.edu

Received 23 January 2018

Revised 10 July 2018

Accepted 16 July 2018

Published Online First

3 August 2018

► <http://dx.doi.org/10.1136/thoraxjnl-2018-212272>

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Park J, Kim S, Lim H, et al. *Thorax* 2019;**74**:43–50.

ABSTRACT

Background We previously reported that microvesicles (MVs) released by human mesenchymal stem cells (MSC) were as effective as the cells themselves in both *Escherichia coli* lipopolysaccharide and live bacteria-induced acute lung injury (ALI) mice models. However, it remained unclear whether the biological effect of MSC MV can be applied to human ALI.

Methods In the current study, we tested the therapeutic effects of MSC MVs in a well-established ex vivo perfused human model of bacterial pneumonia. Using human donor lungs not used for transplantation, we instilled *E. coli* bacteria intrabronchially and, 1 hour later, administered MSC MVs into the perfusate as therapy.

Results After 6 hours, instillation of *E. coli* bacteria caused influx of inflammatory cells, which resulted in significant inflammation, lung protein permeability and pulmonary oedema formation. Administration of MSC MV significantly increased alveolar fluid clearance and reduced protein permeability and numerically lowered the bacterial load in the injured alveolus. The beneficial effect on bacterial killing was more pronounced with pretreatment of MSCs with a Toll-like receptor 3 agonist, polyinosinic:polycytidylic acid (Poly (I:C)), prior to the isolation of MVs. Isolated human alveolar macrophages had increased antimicrobial activity with MSC MV treatment in vitro as well. Although oxygenation and lung compliance levels were similar between injury and treatment groups, administration of MSC MVs numerically decreased median pulmonary artery pressure at 6 hours.

Conclusions In summary, MSC MVs increased alveolar fluid clearance and reduced lung protein permeability, and pretreatment with Poly (I:C) enhanced the antimicrobial activity of MVs in an ex vivo perfused human lung with severe bacteria pneumonia.

INTRODUCTION

Acute respiratory distress syndrome due to bacterial pneumonia and/or sepsis remains a common cause of respiratory failure in critically ill intensive care unit patients with high mortality rates despite appropriate antibiotic use and supportive care.^{1,2} New therapeutic modalities are needed to improve morbidity and mortality. Multiple preclinical studies have demonstrated significant therapeutic potential with mesenchymal stem/stromal cells (MSC) for acute lung injury (ALI) despite limited

Key messages

What is the key question?

► Can the therapeutic effects of mesenchymal stem cells (MSC) microvesicles, as reported in preclinical small animal models of acute lung injury, be applicable to human lung injury models?

What is the bottom line?

► Human bone marrow-derived MSC microvesicles reduced multiple indices of acute lung injury in an ex vivo perfused human lung injured with severe bacterial pneumonia.

Why read on?

► Based on promising results, further studies are warranted in a large animal model of pneumonia with or without sepsis to provide additional preclinical data for possible clinical trials.

engraftment rates of 1%–5%.^{3,4,5} The therapeutic potential of MSCs appeared to arise in part from the secretion of growth factors such as keratinocyte growth factor (KGF),⁶ anti-inflammatory products such as PGE₂ or lipoxin A4,^{7,8} antipermeability factors such as angiopoietin-1 (Ang1),^{9,10} and antimicrobial products such as LL-37 or Lipocalin-2.^{11,12} Based on the significant potential of MSC, several phase I and II clinical trials focused on safety are underway (NCT02097641, NCT01902082, Clinicaltrials.gov).¹³ However, there remains some concerns with allogeneic stem cell therapy such as tumour formation and haemodynamic instability due to their physical properties.

Recently, stem cell-derived therapy, such as MSC conditioned media (CM) or extracellular vesicles, have generated considerable interest due to similar therapeutic properties without the inherent challenges of using live cells. Ionescu *et al*¹⁴ demonstrated that MSC CM reduced lung inflammation and injury following lipopolysaccharide (LPS)-induced ALI in a mouse. Using LPS-induced ALI in an ex vivo perfused human lung, we also found that MSC CM reduced extravascular lung water, improved lung endothelial barrier permeability and restored alveolar fluid clearance (AFC) in part by KGF secretion by MSCs.⁶ More recently, we

demonstrated that MSC-derived extracellular vesicles were as biologically active as MSCs in *Escherichia coli* LPS and bacteria-induced ALI in mice in part through the transfer of mRNA and microRNA to target cells, which resulted in improved resolution of pulmonary oedema and increased antimicrobial activity.^{15,16} We and other investigators also found that pretreatment of MSCs, such as with Poly (I:C),¹⁷ carbon monoxide,¹⁸ hypoxia¹⁹ and so on, may be a viable method to enhance the therapeutic properties of the cells and its released microvesicles (MVs).

Extracellular vesicles, which are released by most cell types, can be broadly classified into exosomes, MVs and apoptotic bodies based largely on their size and origin. Interestingly, extracellular vesicles contain mRNA, microRNA, protein, surface receptors and potentially organelles, which may be involved in their function.^{20–22} However, whether stem cell-derived therapy such as extracellular vesicles can be translated to large animal or even human ALI models is unknown. In the current study, we hypothesised that MSC MVs could be effective in reducing inflammation and total bacterial load in a severe pneumonia model in the ex vivo perfused human lung and that preconditioning MSCs with Poly (I:C) would enhance the antimicrobial properties of the released MVs.

METHODS

Ex vivo perfused human lung and measurement of AFC

Either the right or left lung, from the Northern California Transplant Donor Network, was perfused slowly with DMEM without Phenol Red+5% bovine serum albumin until a cardiac

output of 0.25 L/min was reached and then ventilated (Harvard Apparatus, tidal volume 300 mL, respiratory rate=10/min, fractional inspired oxygen (FiO₂)=21%, and positive end-expiratory pressure (PEEP)=5 cmH₂O) (figure 1).²³ AFC rate was then measured in the control lung lobe by the change in protein concentration of a bronchoalveolar lavage (BAL) fluid over 30 min using the following equation: $AFC (\%/h) = 2 \times (1 - (Ci/Cf)) \times 100$ (Ci and Cf=protein concentration at 5 and 35 min, respectively). If $0 < AFC < 10\%/h$, 10^9 colony forming units (CFU) of *E. coli* bacteria was instilled into the lower lobe, and fresh human blood (100 mL) was added to the perfusate. One hour after injury, either 200 µL of MSC MV (1×), 400 µL of MSC MV (2×), 200 µL of Toll-like receptor 3 (TLR-3) agonist polyinosinic:polycytidylic acid (Poly (I:C)) pretreated MSC MV, or 200 µL of normal human lung fibroblasts (NHLF) MV as cellular control was administered intravenously in a random fashion. At 6 hours, the AFC rate of the injured lobe was measured.

Isolation of MVs derived from human MSCs

MVs were isolated from the conditioned medium of human bone marrow-derived MSCs,²⁴ obtained from a National Institutes of Health repository at Texas A&M Health Science Center, and NHLFs using ultracentrifugation. Briefly, MSCs or NHLFs were grown in a T75 flask until 90% confluency and then serum starved in alpha minimum essential medium (αMEM) or fibroblast basal medium (FBM) supplemented with 0.5% Bovine Albumin Fraction (MP Biomedical LLC). After 48 hours, the conditioned medium was collected and centrifuged at 3000 rpm for 20 min to remove cellular debris and then at 100 000 g

Figure 1 Schematic of the ex vivo perfused human lung preparation. Marginal human lungs that were not used for lung transplantation were obtained from the Northern California Transplantation Donor Network. Using a large organ Harvard bioreactor, the pulmonary artery of the right or left lung was initially cannulated and gently perfused with a crystalloid solution containing 5% albumin at a rate up to 250 mL/min. Once rewarmed, the lung was ventilated using a tidal volume of 300 mL with 5 cmH₂O of PEEP and a respiratory rate 10 breaths per minute in room air. AFC rate was first measured in the upper control lobe. If $AFC > 0$ and $< 10\%/hour$, 10^9 CFU *E. coli* bacteria was administered into the lower lung lobe, and 100 mL of fresh human blood was added to the perfusate. After 6 hours, AFC was measured in the lower lobe as the primary endpoint. In separate experiments and randomly, 200 or 400 µL MSC derived microvesicles (MVs), Poly (I:C) pretreated 200 µL MSC MVs or 200 µL NHLF-derived MVs was administered into the perfusate at 1 hour. AFC, alveolar fluid clearance; LLL, left lower lobe; LUL, left upper lobe; MSC, mesenchymal stem cell; NHLF, normal human lung fibroblasts; Poly (I:C), polyinosinic:polycytidylic acid; RML, right middle lobe; RUL, right upper lobe.

(Beckman Coulter Optima L-100XP Ultracentrifuge) to isolate the MVs for 1 hour twice at 4°C. The final sediment was resuspended in PBS and stored in -80°C. Ten microlitres of the resuspension were equivalent to MVs released by 1 million MSCs or NHLFs over 48 hours.

TLR-3 priming of MSC

In order to switch MSC towards a more immunoregulatory phenotype, TLR-3 agonist, Poly (I:C) (1 µg/mL, Sigma Aldrich), was cultured with MSCs for 1 hour.¹⁷ The cells were then washed twice in PBS and serum starved over 48 hours prior to isolation of MVs.

MSC MV characterisation

MSC MVs were labelled with PKH26 (Sigma Aldrich) to separate out vesicles from debris or with antibodies for CD9-FITC, control IgG1 k-FITC, CD44-FITC or control IgG2b k-FITC (eBioscience and BD Biosciences) for flow cytometry. A BD FACSAria Fusion Special Order (SORP) cell sorter (BD Biosciences) with 100 nm nozzle and ND filter 1 was used. The threshold was set on the SSC 200. Data were analysed by Diva software (BD Biosciences). For fluorescence detection, we used a 586/15 band pass filter for PKH26 and 525/50 band pass filter for fluorescein isothiocyanate (FITC)-labelled antibodies. An unstained sample was used to detect autofluorescence and set the photomultiplier for all the channels. Standard silica beads (Apogee Mix for Flow Cytometer, Apogee Flow Systems), with a similar refractive index of vesicles, was used to gate the MSC MVs. MSC MVs were also characterised by scanning electron microscopy and by using NanoSight NS 300 (Malvern Instruments).

Measurement of lung protein permeability using Evans Blue

At time T5 hours, we injected 400 mg of Evans Blue (Sigma Aldrich) into the perfusate. At time T6.5 hours, 1 mL of perfusate was removed, and then 2 L of PBS was used to flush the lung. Several pieces (1–2 g) from both control and injured lung lobes were then collected and incubated with formamide for 3 days to release the dye. We measured the concentration of Evans blue dye from each sample to calculate lung protein permeability.

Isolation and bacterial killing effect of human alveolar macrophage

Human alveolar macrophages were isolated following BAL with warm normal saline and plated with RPMI 1640 media in a transwell plate (200 000 cell/well) after washing twice with HBSS solution and stimulated with 1 µg/mL LPS with or without 90 µL of MSC MV. The next day, the cells were cultured with

opsonized 10^7 CFU of *E. coli* bacteria for 90 min. The CFU of *E. coli* in the medium was then counted.

Statistical analysis

Results were expressed as the mean ± SD or median with 25%–75% percentile (IQR), as appropriate. Whether the samples were normally distributed was determined by D'Agostino & Pearson or Shapiro-Wilk normality test. Comparisons between several groups were made using the analysis of variance with Bonferroni correction if normally distributed or by Kruskal-Wallis test followed by post hoc Dunn's tests if not. We used the software GraphPad Prism 7.0c.

RESULTS

Baseline demographics and clinical data for donor human lungs

The demographic and clinical data for 37 donor lungs used are listed in the table 1. There appeared to be no major differences between the MV treatment groups compared with *E. coli* injury group in terms of age, sex, partial pressure of oxygen (PaO_2)/ FiO_2 ratio, lung ischaemic time and lung injury score.

MSC MV characterisation

Scanning electron microscopy showed that the isolation technique yielded homogeneous population of spheroid particles (online supplemental figure 1). NanoSight analyses showed MSC MV mean size was 180 ± 14 nm with a concentration at $4.7 \pm 0.2 \times 10^8$ particles per mL. For flow cytometry, we labelled MSC MV with PKH26 to quantify only membrane bound vesicles and to exclude debris. As a percentage of PKH26-labelled MSC MV, we found that $43\% \pm 8\%$ was CD44 positive. An IgG Ab was used as a control to remove background staining. For CD9, only $0.1\% \pm 0.1\%$ of PKH26 MSC MVs was labelled positively, suggesting that the majority of vesicles were MVs. However, since there is significant overlap between exosomes and MVs in terms of size, it is possible that the total number of exosome were under-represented. The MSC MV dose chosen was initially based on prior studies using MSCs in the ex vivo perfused human lung and our observation that MVs were approximately $5\text{--}10\times$ less potent than live cells.²³ Consequently, we administered 200 µL of MSC MVs or the MVs released by 20 million MSCs over 48 hours; previous studies using the ex vivo human lung used 5–10 million MSCs as a therapeutic.

MSC MVs improved AFC in lungs injured following *E. coli* pneumonia

Administration of either human MSC MVs ($1\times$ or $2\times$) or the Poly (I:C) MSC MVs into the perfusate at 1 hour following

Table 1 Clinical data of donor lungs

	<i>Escherichia coli</i> Pneumonia (n=9)	+MSCMV $1\times$ (n=6)	+MSCMV $2\times$ (n=6)	+Poly (I:C) MSC MV (n=11)	+NHLF MV (n=5)
Mean age (year)	44±10	54±16	52±21	50±13	48±22
Male % (n)	56% (5)	83% (5)	67% (4)	73% (8)	80% (4)
Donor $\text{PaO}_2/\text{FiO}_2$ ratio (mm Hg)	221±13	112±33	238±44	251±38	156±70
Ischaemic time (hour:min)	36:38±8:40	32:36±7:42	24:55±11:05	29:09±6:38	28:40±3:26
Lung injury score	1.4±0.6	1.9±0.4	1.2±0.4	1.3±0.4	1.9±0.7

Data are presented as mean ± SD.

FiO_2 , fractional inspired oxygen; MSC, mesenchymal stem cell; MV, microvesicle; NHLF, normal human lung fibroblasts; PaO_2 , arterial oxygen tension (or pressure); Poly (I:C), polyinosinic:polycytidylic acid.

Figure 2 Therapeutic effect of MSC MVs on alveolar fluid clearance rate (AFC) following severe *Escherichia coli* pneumonia in ex vivo perfused human lung. (A) Administration of MSC MVs or Poly (I:C) pretreated MSC MVs intravenously significantly increased the AFC rate in the lung lobe injured by *E. coli* pneumonia at 6 hours. Administration of NHLF MVs had no beneficial effect on AFC rate. AFC was measured by the change in protein concentration of a 5% albumin instillate in the lung lobe over 1 hour and expressed as mean AFC (% per h, per 150 mL of BAL fluid) with 95% CIs for each condition. n=9 for *E. coli*-injured lung lobe, n=6 for *E. coli*-injured lung lobe treated with MSC MVs (200 μ L or 400 μ L) or n=11 for 200 μ L MSC MVs pretreated Poly (I:C) or n=5 for 200 μ L NHLF MVs. Overall p value <0.001; *p is significant versus control, **p is significant versus *E. coli* injured and ***p is significant versus NHLF MVs by analysis of variance (Bonferroni). P values and CIs for individual pair comparisons are shown in supplementary table. (B) Human lungs injured with *E. coli* bacteria with and without MSC MVs 1x or Poly (I:C) pretreated MSC MVs were fixed in 10% formalin at 6 hours. Sections were stained with H&E. Administration of human MSC MVs 1x or Poly (I:C) pretreated MSC MVs 1 hour after *E. coli* pneumonia injury reduced the level of haemorrhage, oedema and cellularity in the injured lung lobe at 6 hours following *E. coli* pneumonia. MSC, mesenchymal stem cell; MVs, microvesicles; NHLF, normal human lung fibroblasts; Poly (I:C), polyinosinic:polycytidylic acid.

E. coli-induced ALI significantly increased AFC at 6 hours by 247% ($p < 0.001$), 159% ($p = 0.001$) or 180% ($p < 0.001$), respectively. The AFC values were also significantly elevated compared with the control lung lobe by 144% ($p < 0.001$), 82% ($p = 0.008$) or 97% ($p < 0.001$), respectively, suggesting a restoration and an improvement. In contrast, administration of NHLF MVs had no benefit and actually significantly decreased AFC compared with the control group ($p = 0.002$) (figure 2A). Surprisingly, there was no dose effect with increasing MSC MV by 2x on any parameter, suggesting that there was a therapeutic ceiling to the MVs. By histology, instillation of intrabronchial *E. coli* bacteria caused significant injury as depicted by an increase in cellularity and blood, oedema and interstitial thickening, which was substantially reduced with the administration of either MSC MV (1x or 2x) or Poly (I:C) MSC MVs (figure 2B).

Poly (I:C) MSC MVs decreased bacterial count in the injured alveolus

Bacterial CFUs were measured in the BAL fluid following instillation of 10^9 *E. coli* bacteria with or without MV treatment at 6 hours. Although the median values of CFU levels in the MSC MV 1x and 2x treatment groups were numerically lower than the *E. coli* injury group, only the administration of Poly (I:C) MSC MVs significantly decreased CFU counts compared with the *E. coli* injured group at 6 hours by post hoc Dunn's analyses following Kruskal-Wallis test ($p = 0.007$). (figure 3A). Administration of

NHLF MVs had no significant effect. The bacterial CFU counts in perfusate were also numerically lower in the MSC MV 2x and Poly (I:C) MSC MV groups compared with *E. coli* group at 6 hours but not statistically significant (figure 3B).

When freshly isolated human alveolar macrophages were cocultured with *E. coli* bacteria with or without LPS and/or MSC MVs, bacterial phagocytosis by alveolar macrophages significantly increased with MSC MV treatment ($p = 0.044$) (figure 3C).

MSC MVs decreased absolute neutrophil count in the injured alveolus

Absolute neutrophil counts in the BAL fluid following *E. coli* pneumonia were numerically lower following administration of MSC MV (1x) or Poly (I:C) MSC MV at 6 hours (median 9.1×10^6 with IQR of 8.6×10^6 – 2.6×10^7 for *E. coli*, median 5.5×10^6 with IQR of 3.9×10^6 – 9.1×10^6 for +MSCMV 1X, median 7.2×10^6 with IQR of 4.7×10^6 – 9.9×10^6 for +Poly (I:C) MSC MV, n=6–11), with overall p value of 0.024 (figure 4A). However, no pair comparisons showed statistical significance after Dunn's correction. There were also no significant differences in absolute neutrophil counts in the perfusate (data not shown).

MSC MVs decreased lung protein permeability

Lung protein permeability was measured in all lung lobes using the extravasation of Evans Blue dye, similar to the technique

Figure 3 Therapeutic effect of MSC MVs on bacterial levels following severe *Escherichia coli* pneumonia in ex vivo perfused human lung. Administration of Poly (I:C) pretreated MSC MVs decreased (A) bacterial counts in the BAL fluid at 6 hours. Administration of NHLF MVs had no beneficial effect. Data are expressed in the box plot as median bacterial CFU counts with IQR for bars in the BAL fluid. Overall p value=0.016; **p is significant versus *E. coli* injury group by post hoc Dunn's analyses following Kruskal-Wallis Test. (B) Although not statistically significant, administration of MSC MVs or Poly (I:C) pretreated MSC MVs numerically decreased bacterial CFU counts in the perfusate. Data are expressed in the graph as median bacterial CFU counts with IQR for bars in the perfusate. Overall p value =0.624. (C) Coincubation of MSC MVs with freshly isolated human alveolar macrophages also increased *E. coli* bacterial phagocytosis by the macrophages. Data are expressed in the graph as median bacterial CFU counts (as % of LPS control) with IQR for bars. Overall p value=0.026; *p is significant versus LPS-treated group by post hoc Dunn's analyses following Kruskal-Wallis test. P values and CIs for individual pair comparisons are shown in supplementary table. CFU, colony forming units; LPS, lipopolysaccharide; MSC, mesenchymal stem cell; MVs, microvesicles; NHLF, normal human lung fibroblasts.

used in mice (figure 5A). Administration of MSC MVs (1× or 2×) or Poly (I:C) MSC MVs significantly reduced lung protein permeability (p=0.001–0.003) (figure 5B).

Effects of MSC MVs on pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR)

PAP was measured throughout the duration of the experiment. Although not statistically significant, administration of MSC MVs or Poly (I:C) MSC MVs lowered PAP at T6 hours compared with the *E. coli* injury group (median 3.6 with IQR of 0–18 for *E. coli*, median 0.2 with IQR of 0–3.3 for +MSCMV 1×, median 0 with IQR of 0–1.4 for +MSCMV 2×, median 0 with IQR of 0–1.1 for +Poly (I:C) MSC MV, n=6–11) (figure 6A). PVR followed a similar trend (figure 6B).

No effect of MSC MVs on tracheal pressure, lung compliance or oxygenation

There were no significant differences in tracheal pressure or lung compliance between control and treatment groups (figure 7A,B). There was also no change in PaO₂ between groups (figure 7C), possibly due to the short duration of the experiment and the technique used to measure AFC.

Effect of MSC MV on tumour necrosis factor (TNF)α levels in the injured alveolus

We measured the inflammatory cytokine (TNFα) in the BAL fluid. Although not statistically significant, administration of human MSC MV 1× after *E. coli* pneumonia numerically reduced the levels of TNFα (pg/ml) by 72% (median 5285 with IQR of 3446–13 409 for *E. coli*, median 1454 with IQR of 681–8097 for +MSCMV 1×, median 5105 with IQR of 3263–9285 for +MSCMV 2X, median 6123 with IQR of 1766–9152 for +Poly (I:C) MSC MV, n=6–11).

DISCUSSION

The main findings of these studies can be summarised as follows: (1) intravenous administration of MSC MVs significantly increased the rate of AFC and decreased lung protein permeability and numerically lowered the CFU bacteria counts and inflammation in the injured alveolus following severe *E. coli* pneumonia in an ex vivo perfused human lung (figures 2, 3 and 5); (2) Poly (I:C) pretreatment of MSCs significantly enhanced the antimicrobial property of the released MVs in the injured alveolus (figure 3); (3) increased antimicrobial effect of Poly (I:C) MSC MVs was associated with a numerically lower influx of inflammatory cells (ie, neutrophils) in the injured lung (figure 4); (4) MSC MVs and Poly (I:C) MSC MVs treatment

Figure 4 Effect of MSC MVs on the influx of inflammatory cells following severe *Escherichia coli* pneumonia in ex vivo perfused human lung. Instillation of MSC MVs numerically decreased the influx of inflammatory cells, specifically neutrophils, into the lung lobe injured by *E. coli* pneumonia at 6 hours. Absolute neutrophil count is expressed as median with IQR for bars for each condition, n=9 for *E. coli* injured lung lobe, n=6–11 for *E. coli*-injured lung lobe treated with 200 μ L or 400 μ L of MSC MVs or 200 μ L of Poly (I:C) pretreated MSC MVs. Overall p value = 0.024. P values and CIs for individual pair comparisons are shown in supplementary table. MSC, mesenchymal stem cell; MVs, microvesicles.

groups had numerically lower median PAP and PVR levels at 6 hours (figure 6). However, MSC MVs and Poly (I:C) MSC MVs did not improve tracheal pressure, lung compliance or oxygenation (figure 7); (5) freshly isolated human alveolar macrophage had enhanced antimicrobial properties with MSC MV treatment (figure 3); and (6) more significantly, the preclinical therapeutic findings seen with MSC MVs in mice were apparent in a clinically relevant human lung injury model, especially in the effect of Poly (I:C) MSC MVs, making it a possible viable alternative to MSCs as a therapy.

Figure 5 Therapeutic effect of MSC MVs on lung protein permeability following severe *Escherichia coli* pneumonia in ex vivo perfused human lung. Lung protein permeability at 6 hours as measured by Evan's Blue extravasation. (A) Administration of Evan's Blue intravenously demonstrated albumin protein leak into the *E. coli* bacteria injured lung lobe. (B) Compared with *E. coli* bacteria injured lung lobe, administration of MSC MVs or Poly (I:C) pretreated MSC MVs significantly reduced lung protein permeability. Data are presented as mean change in permeability with 95% CIs. Overall p value = 0.001. *P is significant versus *E. coli* by analysis of variance (Bonferroni). P values and CIs for individual pair comparisons are shown in supplementary table. MSC, mesenchymal stem cell; MVs, microvesicles; Poly (I:C), polyinosinic:polycytidylic acid.

Most cell types release MVs,²⁵ which can be biologically active as mediators of cell-to-cell communication or through direct effects on target cells.^{26–28} Recently, MVs derived from MSC have been reported to exert therapeutic effects on various organ injury models.^{29–30} We previously found that MSC MV significantly reduced pulmonary oedema in mice injured with LPS or *E. coli* pneumonia^{15–16} and an ex vivo perfused human lung model of ischaemia/reperfusion.³¹ However, the underlying mechanisms were not fully known. In the current study, both MSC MVs and Poly (I:C) MSC MVs improved AFC to a near-normal level at 6 hours following *E. coli* pneumonia (figure 2). We previously demonstrated that MSC and/or MSC MVs increased AFC rate in part through enhanced KGF expression; KGF secreted from MSCs upregulated the key sodium channel (α ENaC) in alveolar epithelial cells, increasing fluid absorption.⁶

We also found that Poly (I:C) MSC MVs enhanced bacterial killing in vivo and MSC MVs in vitro (figure 3) and numerically reduced the influx of neutrophils (figure 4) into the injured alveolus. Several potential mechanisms may account for these observations: (1) MSC and MSC MVs secrete or enhance the expression of antimicrobial soluble factors. Krasnodembskaya *et al* found that MSCs secreted LL-37, a known antimicrobial peptide, and Gupta *et al*^{11–12} demonstrated that MSCs enhanced survival and bacterial clearance through upregulation of Lipocalin-2 by MSCs in a mice model of *E. coli* pneumonia; (2) Raffaghello *et al*³² demonstrated that MSCs inhibited apoptosis of neutrophils by MSC through downregulation of reactive oxygen species and Stat-3 phosphorylation; and (3) multiple groups demonstrated that MSC and MSC MVs enhanced alveolar macrophage survival via mitochondria transfer (via tunnelling nanotubes) and phenotypic change from the proinflammatory M1 to the anti-inflammatory M2.^{33–35} Both Nemeth *et al* and Mei *et al*^{7–36} found that MSCs upregulated macrophage phagocytic activity, which improved bacterial clearance in a caecal ligation and puncture model of sepsis. In addition, recent studies indicated that TLR-3 activation with Poly (I:C) can enhance the immunomodulatory potential of MSC, while TLR-4 activation could reduce it.¹⁷ In

Figure 6 Effect of MSC MVs on pulmonary arterial pressure and vascular resistance following severe *Escherichia coli* pneumonia in ex vivo perfused human lung. Administration of MSC MVs or Poly (I:C) pretreated MSC MVs numerically decreased PAP (A) or PVR (B) at T6 hours compared with *E. coli* injury group. Data are presented as median PAP or PVR with IQR as bars. $P=0.20\text{--}0.66$ for each time point by Kruskal-Wallis tests (A). $P=0.20\text{--}0.63$ for each time point by Kruskal-Wallis tests (B). MSC, mesenchymal stem cell; MVs, microvesicles; PAP, pulmonary arterial pressure; Poly (I:C), polyinosinic:polycytidylic acid; PVR, pulmonary vascular resistance.

a mice model of *E. coli* pneumonia, we found that Poly (I:C) pretreatment of MSC MV enhanced macrophage/monocyte phenotypic M2 change, as indicated by decreased inflammation and increased bacteria phagocytosis.¹⁶

MSC MVs and Poly (I:C) MSC MVs both significantly reduced lung protein permeability (figure 5), which may be attributed to its Ang1 content, a protein with well-known anti-inflammatory,

antipermeability and endothelial protective characteristics. Both MSCs and MSC MVs have significant levels of Ang1 mRNA. In LPS-induced ALI in mice, MSC or MSC transfected with the human Ang1 gene reduced pulmonary vascular injury and the recruitment of inflammatory cells into the lung.¹⁰ More recently, Tang *et al*³⁷ found that Ang1 in MSC MV was important in reducing inflammation and pulmonary oedema in LPS-induced ALI in mice.

Figure 7 Lack of a therapeutic effect of MSC MVs on lung compliance or oxygenation following severe *Escherichia coli* pneumonia in ex vivo perfused human lung. Administration of MSC MVs or Poly (I:C) pretreated MSC MVs had no significant effect on tracheal pressure (A), lung compliance (B) or oxygenation (C) over 6 hours. Data are presented as median tracheal pressure or lung compliance or PaO_2 with IQR as bars. $P=0.56\text{--}0.98$ for each time point by Kruskal-Wallis tests (A). $P=0.56\text{--}0.98$ for each time point by Kruskal-Wallis tests (B). $P=0.10\text{--}0.92$ for each time point by Kruskal-Wallis tests (C). MSC, mesenchymal stem cell; MVs, microvesicles; PaO_2 , arterial oxygen tension (or pressure); Poly (I:C), polyinosinic:polycytidylic acid.

Our study has some limitations: (1) lack of an intact lymphatic system for lung interstitial fluid clearance, which may be relevant if AFC is measured over longer periods; (2) lack of other immune organs such as the spleen or liver, which may participate in injury and/or repair; (3) short duration of lung injury, which limits assessment of whether the effects of MSC MVs can be sustained; and (4) limited sample size due to lack of availability of lungs for research.

Despite the limitations, the importance of the current study was in establishing the use of MVs as a possible viable alternative to using live cells in ALI. The benefits include ease of isolation and storage, avoiding dimethyl sulfoxide for preservation and the need for a bone marrow transplant facility, avoidance of using live stem cells with tumourigenic potential and which may cause haemodynamic instability with administration and potential to modify MVs with pretreatment of the cells to enhance the therapeutic effects. However, the major obstacle remains in scaling the production of MSC MVs since the potency is approximately 5–10× less than the cells. Given that a typical MSC dose is 5 million cells/kg or 500 million cells for a 100 kg patient, future clinical trials with MSC MVs may require isolating MVs released from up to 5 billion cells per patient, which may be prohibitive. Studies are ongoing to address this critical issue.

In conclusion, our study demonstrated that MSC MVs was therapeutic in a clinically relevant human model of severe *E. coli* pneumonia in lungs with baseline injury. Based on these promising results, further studies are warranted in a large animal with pneumonia and or sepsis to provide further biological rationale and additional preclinical data for possible clinical trials.

Contributors JP: conception and design, collection and assembly of data, data analysis and interpretation, and manuscript writing. SK, HL, AL, SH, JL, HZ and QH: collection and assembly of data and data analysis and interpretation. MAM: financial support, data analysis and interpretation and manuscript writing. J-WL: conception and design, financial support, data analysis and interpretation, manuscript writing and final approval.

Funding This work was supported by the National Institute of Health National Heart, Lung, and Blood Institute grant number HL-113022 (Dr J-W Lee), HL-51856 and HL-131621 (Dr M A Matthay).

Competing interests None declared.

Patient consent Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- Ware LB, Matthay MA. The acute respiratory distress syndrome. *N Engl J Med* 2000;342:1334–49.
- Luo L, Shaver CM, Zhao Z, et al. Clinical Predictors of Hospital Mortality Differ Between Direct and Indirect ARDS. *Chest* 2017;151:755–63.
- Kotton DN, Fabian AJ, Mulligan RC. Failure of bone marrow to reconstitute lung epithelium. *Am J Respir Cell Mol Biol* 2005;33:328–34.
- Loi R, Beckett T, Goncz KK, et al. Limited restoration of cystic fibrosis lung epithelium in vivo with adult bone marrow-derived cells. *Am J Respir Crit Care Med* 2006;173:171–9.
- Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. *Science* 1999;284:143–7.
- Lee JW, Fang X, Gupta N, et al. Allogeneic human mesenchymal stem cells for treatment of *E. coli* endotoxin-induced acute lung injury in the ex vivo perfused human lung. *Proc Natl Acad Sci U S A* 2009;106:16357–62.
- Németh K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. *Nat Med* 2009;15:42–9.
- Fang X, Abbott J, Cheng L, et al. Human Mesenchymal Stem (Stromal) Cells Promote the Resolution of Acute Lung Injury in Part through Lipoxin A4. *J Immunol* 2015;195:875–81.
- Fang X, Neyrinck AP, Matthay MA, et al. Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1. *J Biol Chem* 2010;285:26211–22.
- Mei SH, McCarter SD, Deng Y, et al. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. *PLoS Med* 2007;4:e269.
- Krasnodembskaya A, Song Y, Fang X, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. *Stem Cells* 2010;28:2229–38.
- Gupta N, Krasnodembskaya A, Kapetanaki M, et al. Mesenchymal stem cells enhance survival and bacterial clearance in murine *Escherichia coli* pneumonia. *Thorax* 2012;67:533–9.
- Liu KD, Wilson JG, Zhuo H, et al. Design and implementation of the START (Stem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome. *Ann Intensive Care* 2014;4:22.
- Ionescu L, Byrne RN, van Haften T, et al. Stem cell conditioned medium improves acute lung injury in mice: in vivo evidence for stem cell paracrine action. *Am J Physiol Lung Cell Mol Physiol* 2012;303:L967–L977.
- Zhu YG, Feng XM, Abbott J, et al. Human mesenchymal stem cell microvesicles for treatment of *Escherichia coli* endotoxin-induced acute lung injury in mice. *Stem Cells* 2014;32:116–25.
- Monsel A, Zhu YG, Gennai S, et al. Therapeutic Effects of Human Mesenchymal Stem Cell-derived Microvesicles in Severe Pneumonia in Mice. *Am J Respir Crit Care Med* 2015;192:324–36.
- Waterman RS, Tomchuck SL, Henkle SL, et al. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. *PLoS One* 2010;5:e10088.
- Tsoyi K, Hall SR, Dalli J, et al. Carbon Monoxide Improves Efficacy of Mesenchymal Stromal Cells During Sepsis by Production of Specialized Proresolving Lipid Mediators. *Crit Care Med* 2016;44:e1236–e1245.
- Han KH, Kim AK, Kim MH, et al. Enhancement of angiogenic effects by hypoxia-preconditioned human umbilical cord-derived mesenchymal stem cells in a mouse model of hindlimb ischemia. *Cell Biol Int* 2016;40:27–35.
- Biancone L, Bruno S, Deregibus MC, et al. Therapeutic potential of mesenchymal stem cell-derived microvesicles. *Nephrol Dial Transplant* 2012;27:3037–42.
- Willis GR, Fernandez-Gonzalez A, Anastas J, et al. Mesenchymal Stromal Cell Exosomes Ameliorate Experimental Bronchopulmonary Dysplasia and Restore Lung Function through Macrophage Immunomodulation. *Am J Respir Crit Care Med* 2018;197:104–16.
- Matthay MA, Pati S, Lee JW. Concise Review: Mesenchymal Stem (Stromal) Cells: Biology and Preclinical Evidence for Therapeutic Potential for Organ Dysfunction Following Trauma or Sepsis. *Stem Cells* 2017;35:316–24.
- Lee JW, Krasnodembskaya A, McKenna DH, et al. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. *Am J Respir Crit Care Med* 2013;187:751–60.
- Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006;8:315–7.
- Hirsova P, Ibrahim SH, Verma VK, et al. Extracellular vesicles in liver pathobiology: Small particles with big impact. *Hepatology* 2016;64:2219–33.
- Schorey JS, Harding CV. Extracellular vesicles and infectious diseases: new complexity to an old story. *J Clin Invest* 2016;126:1181–9.
- Pitt JM, Kroemer G, Zitvogel L. Extracellular vesicles: masters of intercellular communication and potential clinical interventions. *J Clin Invest* 2016;126:1139–43.
- Zappulli V, Friis KP, Fitzpatrick Z, et al. Extracellular vesicles and intercellular communication within the nervous system. *J Clin Invest* 2016;126:1198–207.
- Gatti S, Bruno S, Deregibus MC, et al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. *Nephrol Dial Transplant* 2011;26:1474–83.
- Lai RC, Arslan F, Lee MM, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. *Stem Cell Res* 2010;4:214–22.
- Gennai S, Monsel A, Hao Q, et al. Microvesicles Derived From Human Mesenchymal Stem Cells Restore Alveolar Fluid Clearance in Human Lungs Rejected for Transplantation. *Am J Transplant* 2015;15:2404–12.
- Raffaghelli L, Bianchi G, Bertolotto M, et al. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. *Stem Cells* 2008;26:151–62.
- Islam MN, Das SR, Emin MT, et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. *Nat Med* 2012;18:759–65.
- Phinney DG, Di Giuseppe M, Njah J, et al. Mesenchymal stem cells use extracellular vesicles to outsource mitochondria and shuttle microRNAs. *Nat Commun* 2015;6:8472.
- Morrison TJ, Jackson MV, Cunningham EK, et al. Mesenchymal Stromal Cells Modulate Macrophages in Clinically Relevant Lung Injury Models by Extracellular Vesicle Mitochondrial Transfer. *Am J Respir Crit Care Med* 2017;196:1275–86.
- Mei SH, Haitsma JJ, Dos Santos CC, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. *Am J Respir Crit Care Med* 2010;182:1047–57.
- Tang XD, Shi L, Monsel A, et al. Mesenchymal Stem Cell Microvesicles Attenuate Acute Lung Injury in Mice Partly Mediated by Ang-1 mRNA. *Stem Cells* 2017;35:1849–59.